KR102800284B1 - Lpa 길항제로서의 시클로헵틸 산 - Google Patents

Lpa 길항제로서의 시클로헵틸 산 Download PDF

Info

Publication number
KR102800284B1
KR102800284B1 KR1020217011086A KR20217011086A KR102800284B1 KR 102800284 B1 KR102800284 B1 KR 102800284B1 KR 1020217011086 A KR1020217011086 A KR 1020217011086A KR 20217011086 A KR20217011086 A KR 20217011086A KR 102800284 B1 KR102800284 B1 KR 102800284B1
Authority
KR
South Korea
Prior art keywords
independently
lpa
alkyl
pharmaceutically acceptable
cycloalkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020217011086A
Other languages
English (en)
Korean (ko)
Other versions
KR20210060547A (ko
Inventor
피터 타이 와 쳉
준 시
시웨이 타오
Original Assignee
브리스톨-마이어스 스큅 컴퍼니
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 브리스톨-마이어스 스큅 컴퍼니 filed Critical 브리스톨-마이어스 스큅 컴퍼니
Publication of KR20210060547A publication Critical patent/KR20210060547A/ko
Application granted granted Critical
Publication of KR102800284B1 publication Critical patent/KR102800284B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
KR1020217011086A 2018-09-18 2019-09-16 Lpa 길항제로서의 시클로헵틸 산 Active KR102800284B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862732595P 2018-09-18 2018-09-18
US62/732,595 2018-09-18
PCT/US2019/051275 WO2020060916A1 (en) 2018-09-18 2019-09-16 Cycloheptyl acids as lpa antagonists

Publications (2)

Publication Number Publication Date
KR20210060547A KR20210060547A (ko) 2021-05-26
KR102800284B1 true KR102800284B1 (ko) 2025-04-23

Family

ID=68073224

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020217011086A Active KR102800284B1 (ko) 2018-09-18 2019-09-16 Lpa 길항제로서의 시클로헵틸 산

Country Status (7)

Country Link
US (1) US20220041572A1 (cg-RX-API-DMAC7.html)
EP (1) EP3852747B1 (cg-RX-API-DMAC7.html)
JP (1) JP7429224B2 (cg-RX-API-DMAC7.html)
KR (1) KR102800284B1 (cg-RX-API-DMAC7.html)
CN (1) CN112702998A (cg-RX-API-DMAC7.html)
ES (1) ES2948793T3 (cg-RX-API-DMAC7.html)
WO (1) WO2020060916A1 (cg-RX-API-DMAC7.html)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7412424B2 (ja) * 2018-09-18 2024-01-12 ブリストル-マイヤーズ スクイブ カンパニー Lpaアンタゴニストとしてのオキサビシクロ酸
ES2946657T3 (es) * 2018-09-18 2023-07-24 Bristol Myers Squibb Co Acidos ciclopentílicos como antagonistas de LPA
CN114728168B (zh) 2019-11-15 2024-04-09 吉利德科学公司 三唑氨基甲酸酯吡啶基磺酰胺作为lpa受体拮抗剂及其用途
TWI843503B (zh) 2020-06-03 2024-05-21 美商基利科學股份有限公司 Lpa受體拮抗劑及其用途
US11702407B2 (en) 2020-06-03 2023-07-18 Gilead Sciences, Inc. LPA receptor antagonists and uses thereof
AU2022273631B2 (en) 2021-05-11 2025-04-17 Gilead Sciences, Inc. Lpa receptor antagonists and uses thereof
KR20240007233A (ko) * 2021-05-13 2024-01-16 길리애드 사이언시즈, 인코포레이티드 Lpa 수용체 길항제 및 이의 용도
US11939318B2 (en) 2021-12-08 2024-03-26 Gilead Sciences, Inc. LPA receptor antagonists and uses thereof
TW202342017A (zh) 2022-02-25 2023-11-01 美商洛子峰生物有限公司 用於治療與lpa受體活性相關的病狀的化合物及組合物
IL326963A (en) 2023-09-08 2026-05-01 Haisco Pharmaceutical Group Co Ltd LPAR1 antagonist and its use
WO2026061483A1 (zh) * 2024-09-19 2026-03-26 西藏海思科制药有限公司 一种lpar1拮抗剂及其用途

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011071570A1 (en) 2009-12-08 2011-06-16 Abbott Laboratories Novel oxadiazole compounds
WO2017223016A1 (en) 2016-06-21 2017-12-28 Bristol-Myers Squibb Company Carbamoyloxymethyl triazole cyclohexyl acids as lpa antagonists

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1364659B1 (en) 2001-02-08 2009-11-11 Ono Pharmaceutical Co., Ltd. Remedies for urinary diseases comprising lpa receptor controlling agents
US20080186971A1 (en) 2007-02-02 2008-08-07 Tarari, Inc. Systems and methods for processing access control lists (acls) in network switches using regular expression matching logic
US9527807B2 (en) 2011-04-05 2016-12-27 Takeda Pharmaceutical Company Limited Sulfonamide derivative and use thereof
SG11201407220YA (en) 2012-06-20 2014-12-30 Hoffmann La Roche N-alkyltriazole compounds as lpar antagonists
JP7412424B2 (ja) 2018-09-18 2024-01-12 ブリストル-マイヤーズ スクイブ カンパニー Lpaアンタゴニストとしてのオキサビシクロ酸
ES2946657T3 (es) 2018-09-18 2023-07-24 Bristol Myers Squibb Co Acidos ciclopentílicos como antagonistas de LPA

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011071570A1 (en) 2009-12-08 2011-06-16 Abbott Laboratories Novel oxadiazole compounds
WO2017223016A1 (en) 2016-06-21 2017-12-28 Bristol-Myers Squibb Company Carbamoyloxymethyl triazole cyclohexyl acids as lpa antagonists

Also Published As

Publication number Publication date
JP2022500469A (ja) 2022-01-04
WO2020060916A1 (en) 2020-03-26
ES2948793T3 (es) 2023-09-19
EP3852747A1 (en) 2021-07-28
US20220041572A1 (en) 2022-02-10
CN112702998A (zh) 2021-04-23
KR20210060547A (ko) 2021-05-26
JP7429224B2 (ja) 2024-02-07
EP3852747B1 (en) 2023-05-31

Similar Documents

Publication Publication Date Title
KR102702231B1 (ko) Lpa 길항제로서의 피라졸 o-연결된 카르바모일 시클로헥실 산
KR102756637B1 (ko) Lpa 길항제로서의 이속사졸 n-연결된 카르바모일 시클로헥실 산
KR102756639B1 (ko) Lpa 길항제로서의 시클로헥실 산 이속사졸 아졸
KR102698386B1 (ko) Lpa 길항제로서의 피라졸 n-연결된 카르바모일 시클로헥실 산
KR102828422B1 (ko) Lpa 길항제로서의 시클로헥실 산 이속사졸 아진
KR102702229B1 (ko) Lpa 길항제로서의 트리아졸 n-연결된 카르바모일 시클로헥실 산
KR102697358B1 (ko) Lpa 길항제로서의 이속사졸 o-연결된 카르바모일 시클로헥실 산
KR102726939B1 (ko) Lpa 길항제로서의 시클로헥실 산 피라졸 아졸
KR102725744B1 (ko) Lpa 길항제로서의 시클로헥실 산 피라졸 아진
KR102791678B1 (ko) Lpa 길항제로서의 시클로부틸 카르복실산
KR102788997B1 (ko) Lpa 길항제로서의 옥사비시클로 산
JP7429224B2 (ja) Lpaアンタゴニストとしてのシクロヘプチル酸
KR102963816B1 (ko) Lpa 길항제로서의 이속사졸 카르복실산

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20210414

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20220704

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20240819

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20250415

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20250421

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20250421

End annual number: 3

Start annual number: 1

PG1601 Publication of registration